We use cookies for a better user experience. Read our Privacy Policy
I Agree
Oncolytic Virus Immunotherapy Market
Due to advancements in medical science and technology, at present, immunotherapy is at the helm of modern oncology care due to which, the deployment of oncolytic virus immunotherapy has witnessed consistent growth. A spectrum of immunotherapies that primarily target three major layers of tumor biology, including immune system, niche, and tumor has gained considerable traction due to promising end-results. Oncolytic virus immunotherapy is an emerging primary as well as salvage therapy around the world and as per current observations, the trend is likely to continue during the forecast period.
Over the past couple of decades, the development of anti-cancer treatment therapies has largely been focused on delivering customized therapy to cellular targets. The promising outcomes during the early stage clinical trials with oncolytic virus immunotherapy are another factor expected to play an imperative role in boosting the overall growth of the oncolytic virus immunotherapy market in the upcoming decade. Research and development activities, increasing collaborations between research institutes and medical colleges, and rising number of cancer patients around the world are some of the primary factors that are expected to drive the global oncolytic virus immunotherapy market during the assessment period.
At the back of these factors, the global oncolytic virus immunotherapy market is expected to cross a market value of ~US$ 2.3 Bn by the end of 2030.
Request a sample to get extensive insights into the Oncolytic Virus Immunotherapy Market
While research and development activities are likely to shift gears during the course of the forecast period, approval from the FDA for various oncolytic virus immunotherapies is projected to drive the oncolytic virus immunotherapy market. In the current scenario, a number of oncolytic viruses are in the pre-clinical and the clinical development stage. In addition, current findings of research indicate that the therapeutic potential of oncolyitc viruses extend beyond melanomas. Over the past decade, oncolytic virus immunotherapy has garnered immense popularity as a novel development in the field of cancer therapies and the trend is set to continue during the forecast period. In addition, oncolytic virus immunotherapy address the underlying challenges associated with traditional therapies, including radiotherapy and chemotherapy due to which, the demand for oncolytic virus immunotherapy has increased worldwide. Oncolytic viruses are likely to influence oncologic care as therapeutic adjuvant– another factor that is projected to propel the demand for oncolytic virus immunotherapy during the forecast period. Moreover, oncolytic virus immunotherapies are likely to address the primary issue of acquired and primary immunotherapeutic resistance.
To understand how our report can bring difference to your business strategy, Ask for a brochure
The oncolytic virus immunotherapy is anticipated to revolutionize the future of cancer treatment. A number of oncolytic virus immunotherapies are in the development phase and likely to hit the oncolytic virus immunotherapy market over the course of the forecast period. Translational and clinical efforts that leverage the findings of research and development activities to curate effective oncolytic virus immunotherapies for cancer patients have gained worldwide popularity in the past few years– a factor that is expected to propel market growth during the assessment period. A number of oncolytic virus platforms are being evaluated in clinical trials, including Adenovirus, Piconavirus, Maraba virus, Reovirus, and Vaccinia virus, among others. While the evaluation of these oncolytic virus platforms continues, the development of new platforms and approaches continues to take shape and offer promise due to which, the prospects of the global oncolytic virus immunotherapy market look bright in the upcoming years. Researchers are also exploring the potential of effective combination immunotherapy by utilizing oncolytic viruses to accurately delivery of chimeric antigen receptor (CAR) targets to solid tumor.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Oncolytic Virus Immunotherapy Market
The advent of the COVID-19 pandemic is expected to have insignificant impact on the overall growth prospects of the global oncolytic virus immunotherapy market. Research and development activities continue to gain notable traction as researchers continue to explore the possibilities of using oncolytic virus immunotherapy tools to curb the transmission of COVID-19 infection. The COVID-19 pandemic has resulted in a dire need for the development of an effective vaccine against the novel coronavirus due to which, research activities are on the rise.
Analysts’ Viewpoint
The global oncolytic virus immunotherapy market is expected to expand at a staggering CAGR of ~32% during the forecast period. The market growth can be primarily attributed to rising prevalence of cancer worldwide, research and development activities, technological advancements, and increasing collaborations between market players and research institutes. At present, market players should focus on exploring the potential benefits of using oncolytic virus immunotherapy tools to contain the spread of the novel coronavirus.
Oncolytic Virus Immunotherapy Market – Segmentation
|
Type |
|
|
Route of Administration |
|
|
Application |
|
|
Region |
|
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
Oncolytic virus immunotherapy market to cross valuation of US$ 2.3 Bn by 2030
Oncolytic virus immunotherapy market is projected to expand at a CAGR of ~32% from 2020 to 2030
Oncolytic virus immunotherapy market is driven by rising number of cancer patients around the world
North America accounted for a major share of the global oncolytic virus immunotherapy market, the trend is anticipated to continue during the forecast period
Key players in the global oncolytic virus immunotherapy market include Amgen, Inc., Merck & Co., Inc. (Viralytics Limited), Shanghai Sunway Biotech Co.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oncolytic Virus Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2018–2030
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.2. Pipeline Analysis
5.3. Key Industry Developments
5.4. Features of oncolytic viruses
6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
6.3.1. Herpes Simplex Virus
6.3.2. Vaccinia Virus
6.3.3. Adenovirus
6.3.4. Reovirus
6.3.5. Others
6.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type
7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
7.3.1. Intratumoral
7.3.2. Intravenous
7.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration
8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
8.3.1. Melanoma
8.3.2. Non-small Cell Lung Cancer (NSCLC)
8.3.3. Pancreatic Cancer
8.3.4. Breast Cancer
8.3.5. Others
8.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application
9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Rest of World
9.3. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Region
10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
10.2.1. Herpes Simplex Virus
10.2.2. Vaccinia Virus
10.2.3. Adenovirus
10.2.4. Reovirus
10.2.5. Others
10.3. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
10.3.1. Intratumoral
10.3.2. Intravenous
10.4. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
10.4.1. Melanoma
10.4.2. Non-small Cell Lung Cancer (NSCLC)
10.4.3. Pancreatic Cancer
10.4.4. Breast Cancer
10.4.5. Others
10.5. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Route of Administration
10.6.3. By Application
10.6.4. By Country
11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
11.2.1. Herpes Simplex Virus
11.2.2. Vaccinia Virus
11.2.3. Adenovirus
11.2.4. Reovirus
11.2.5. Others
11.3. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
11.3.1. Intratumoral
11.3.2. Intravenous
11.4. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
11.4.1. Melanoma
11.4.2. Non-small Cell Lung Cancer (NSCLC)
11.4.3. Pancreatic Cancer
11.4.4. Breast Cancer
11.4.5. Others
11.5. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Route of Administration
11.6.3. By Application
11.6.4. By Country/Sub-region
12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
12.2.1. Herpes Simplex Virus
12.2.2. Vaccinia Virus
12.2.3. Adenovirus
12.2.4. Reovirus
12.2.5. Others
12.3. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
12.3.1. Intratumoral
12.3.2. Intravenous
12.4. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
12.4.1. Melanoma
12.4.2. Non-small Cell Lung Cancer (NSCLC)
12.4.3. Pancreatic Cancer
12.4.4. Breast Cancer
12.4.5. Others
12.5. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Route of Administration
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Rest of World Oncolytic Virus Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030
13.2.1. Herpes Simplex Virus
13.2.2. Vaccinia Virus
13.2.3. Adenovirus
13.2.4. Reovirus
13.2.5. Others
13.3. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030
13.3.1. Intratumoral
13.3.2. Intravenous
13.4. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030
13.4.1. Melanoma
13.4.2. Non-small Cell Lung Cancer (NSCLC)
13.4.3. Pancreatic Cancer
13.4.4. Breast Cancer
13.4.5. Others
13.5. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Route of Administration
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis/Ranking, by Company, 2019
14.3. Company Profiles
14.3.1. Amgen Inc.
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Merck & Co., Inc. (Viralytics Limited)
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Shanghai Sunway Biotech Co., Ltd
14.3.3.1. Company Overview
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. TILT Biotherapeutics
14.3.4.1. Company Overview
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Oncorus, Inc.
14.3.5.1. Company Overview
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. Replimune Group, Inc.
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Oncolys BioPharma, Inc.
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Sorrento Therapeutics, Inc.
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Oncolytics Biotech, Inc.
14.3.9.1. Company Overview
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. SillaJen, Inc.
14.3.10.1. Company Overview
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
List of Table
Table 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 02: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 03: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 04: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 05: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country, 2018–2030
Table 06: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 07: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 08: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030
Table 09: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 10: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 11: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 12: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030
Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030
Table 17: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030
Table 18: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 19: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030
List of Figure
Figure 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2019
Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2019
Figure 04: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2019
Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2019
Figure 06: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2019 and 2030
Figure 07: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030
Figure 08: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Herpes Simplex Virus, 2018–2030
Figure 09: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Vaccinia Virus, 2018–2030
Figure 10: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Adenovirus, 2018–2030
Figure 11: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Reovirus, 2018–2030
Figure 12: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018–2030
Figure 13: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 14: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 15: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intratumoral, 2018–2030
Figure 16: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intravenous, 2018–2030
Figure 17: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2019 and 2030
Figure 18: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 19: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Melanoma, 2018–2030
Figure 20: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Non-small Cell Lung Cancer (NSCLC), 2018–2030
Figure 21: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Pancreatic Cancer, 2018–2030
Figure 22: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Breast Cancer, 2018–2030
Figure 23: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018–2030
Figure 24: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2019 and 2030
Figure 25: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region
Figure 26: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 27: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Country, 2019 and 2030
Figure 28: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2020–2030
Figure 29: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030
Figure 30: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030
Figure 31: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 32: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 33: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030
Figure 34: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 35: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 36: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 37: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 38: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030
Figure 39: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030
Figure 40: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 41: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 42: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030
Figure 43: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 45: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 46: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 47: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030
Figure 48: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030
Figure 49: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 50: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 51: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030
Figure 52: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 53: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 54: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2021 and 2030
Figure 55: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2022–2030
Figure 56: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2021 and 2030
Figure 57: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2022–2030
Figure 58: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2021 and 2030
Figure 59: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022–2030
Figure 60: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019
Figure 61: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2019
Figure 62: Amgen, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019
Figure 63: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019
Figure 64: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2019
Figure 65: Merck & Co., Inc. Breakdown of Net Sales (%), by Business Segment, 2019
Figure 66: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019
Figure 67: Replimune Group, Inc. Total Operating Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2020
Figure 68: Replimune Group, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2019
Figure 69: Oncolys BioPharma, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019
Figure 70: Oncolys BioPharma, Inc. Breakdown of Net Sales (%), by Region/Country, 2019
Figure 71: Sorrento Therapeutics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019
Figure 72: Sorrento Therapeutics, Inc. Breakdown of Net Sales (%), by Business Segment, 2019
Figure 73: Sorrento Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019
Figure 74: Oncolytics Biotech, Inc. Total assets (US$ Mn) and Y-o-Y Growth (%), 2017-2019
Figure 75: Oncolytics Biotech, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019
Complete the form below and we'll get back to you shortly.
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
